Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533599 | PMC |
http://dx.doi.org/10.1186/s44215-023-00111-9 | DOI Listing |
Gen Thorac Cardiovasc Surg Cases
November 2023
Department of Thoracic Surgery, Tokyo Women's Medical University, Kawada-Cho 8-1, Shinjuku-Ku, Tokyo, 162-8666, Japan.
Cureus
October 2024
Radiology, Souss Massa University Hospital, Agadir, MAR.
Background: MK-5475 is an investigational inhaled soluble guanylate cyclase stimulator hypothesised to avoid most side-effects of systemic vasodilation.
Methods: The phase 2 INSIGNIA-PAH (NCT04732221) trial randomised adults with pulmonary arterial hypertension (PAH) on stable background therapy 1:1:1:1 to once-daily dosing with placebo, MK-5475 32 µg, 100 µg or 380 µg dry powder inhalation for 12 weeks.
Objectives: The objectives were to evaluate pulmonary vascular resistance (PVR; primary), 6-min walk distance (6MWD; secondary), additional selected haemodynamic parameters, and safety and tolerability in participants with PAH.
Eur J Case Rep Intern Med
September 2024
Nephrology and Hypertension Department, Samson Assuta Ashdod University Hospital, Ashdod, Israel.
Cureus
July 2024
Department of Internal Medicine, Tubas Turkish Governmental Hospital, Tubas, PSE.
Hodgkin lymphoma (HL), a lymphoid neoplasm characterized by the presence of Reed-Sternberg cells, often presents with painless lymphadenopathy and systemic symptoms. This case report details the diagnostic journey of a 27-year-old non-smoker female with chronic respiratory symptoms, including persistent cough, hemoptysis, and weight loss over two years. Despite multiple treatments for presumed infections and extensive diagnostic procedures, the correct diagnosis of HL was delayed due to atypical pulmonary manifestations, notably necrotizing pneumonia and multiple cavitary lung lesions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!